Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2019

01-03-2019 | Lymphoma | Guide Line

JSH Practical Guidelines for Hematological Malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia–lymphoma

Authors: Kunihiro Tsukasaki, Takuya Fukushima

Published in: International Journal of Hematology | Issue 3/2019

Login to get access

Excerpt

Adult T-cell leukemia–lymphoma (ATL) is a disease concept first described by Uchiyama and Takatsuki et al. in 1977 as a T-cell neoplasm endemic to southwestern Japan, primarily the Kyushu region and Okinawa [1]. Human T-cell leukemia virus type 1 (HTLV-1) was discovered as the causative virus in the early 1980s [2–5]. In the 2017 WHO Classification, ATL is defined as a peripheral T-cell neoplasm caused by HTLV-1 that is composed of lymphocytes with high-grade nuclear atypia [6]. …
Metadata
Title
JSH Practical Guidelines for Hematological Malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia–lymphoma
Authors
Kunihiro Tsukasaki
Takuya Fukushima
Publication date
01-03-2019
Publisher
Springer Japan
Keywords
Lymphoma
Leukemia
Published in
International Journal of Hematology / Issue 3/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-02588-5

Other articles of this Issue 3/2019

International Journal of Hematology 3/2019 Go to the issue

Correction

Correction to: Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia

Case Report

Complete remission of pure white cell aplasia associated with thymoma after thymectomy and cyclosporine administration

Letter to the Editor

Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study

Original Article

Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan

Review Article

Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature

Images in Hematology

Tuberculous lymphadenitis mimicking Castleman disease-like histological features
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits